To investigate the difference of peripheral blood sIL-2R before and after chemotherapy in breast cancer patients, and evaluate the clinical value of the sIL-2R in breast cancer's diagnosis and therapy.Methods
The peripheral blood sIL-2R levels of the breast cancer patients with or without chemotherapy were detected by ELISA. The healthy persons were made as the control group.Results
The sIL-2R levels of the breast cancer patients were higher than that of the control group(P<0.05); the sIL-2R's levels in I˜II stage breast cancer were lower than that in III˜IV stage breast cancer (P<0.05); the sIL-2R levels of the patients before chemotherapy were higher than that of the patients undergone chemotherapy(P<0.05); The level of the patient with chemotherapy was still higher than that of the control group (P<0.05); the sIL-2R levels of the patients whose chemotherapies were noneffective were higher than that of the patients received effective chemotherapies (P<0.05). There was no significant difference between the group with ER(+) or PR(+) and the group with ER(-) or PR(-)(P>0.05).Conclusion
The breast cancer patients have the high sIL-2R levels. There is a close relationship between the cancer incidence and the patients, immune situation. The level of sIL-2R could be a clinical index which can be used for evaluating the cancer degree, because the higher levels of sIL-2R can indicate that the immune ability of patient is worse. There is a significant difference between the sIL-2R levels of the patients before chemotherapy and that of the patients undergone chemotherapy.